相关实验视频

Updated: Jul 8, 2025

A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice

A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice

Published on: April 17, 2019

对神经内分泌瘤的长效索马托他类型的治疗模式

Callisia N Clarke¹, Paul Cockrum², Thomas J R Beveridge²

¹Medical College of Wisconsin, Milwaukee, Wisconsin.

Journal of health economics and outcomes research

|December 14, 2023

概括

在神经内分泌瘤 (NET) 患者中,长效索马托斯塔丁类比疗法 (LA-SSA) 显示,兰类药物提供了较长的治疗持续时间和较少的剂量升级,相比于八类药物LAR. 这表明lanreotide在NET管理中的潜在临床益处.

科学领域:

内分泌学在内分泌学.
在瘤学瘤学.
药理学药理学是指药理学的学科.

背景情况:

长效索马托他类型疗法 (LA-SSA) 是对不可切除或转移的神经内分泌瘤 (NETs) 的推的一线治疗方法.
了解LA-SSA治疗顺序和剂量对于基于价值的NET管理至关重要.
癌症综合征 (CS) 是NET的特定临床表现,通常需要LA-SSA治疗.

研究的目的:

描述和比较现实世界的LA-SSA在美国NET患者的治疗模式.
分析lanreotide和octreotide长效释放 (LAR) 之间的治疗持续时间,剂量升级和救援疗法的差异.
为了评估患有癌症综合征的患者子组的治疗模式.

主要方法:

对2015年1月至2020年10月的美国MarketScan®索赔数据进行了回顾性分析.
鉴定新接受LA-SSA治疗的NET患者,分层分为lanreotide或octreotide LAR.
使用统计测试 (t测试,奇方位,日志等级测试) 进行治疗持续时间,剂量升级率,救援治疗使用和治疗过渡的比较.

主要成果:

兰类患者的治疗持续时间明显更长 (中位数为41.3个月),相比于八类LAR患者 (中位数为26.8个月).
较少的lanreotide患者接受了救援治疗或剂量升级,而不是 octreotide LAR.
兰胺的使用与更少的患者接受标签上方的剂量和更少的转换到其他LA-SSAs停止后相关.

结论:

现实世界的数据表明,在NET管理中使用lanreotide与治疗持续时间的延长和剂量调整的频率较低相比于octreotide LAR.
这些发现表明,lanreotide在维持患者初始治疗方面具有潜在的临床益处.
观察到的模式支持lanreotide作为NET管理的有价值选择,特别是对于需要长期治疗的患者.

关键词:

在标签上方的剂量.剂量升级剂量的升级.兰雷化物是什么神经内分泌瘤的神经内分泌瘤长效释放性八丁胺的使用情况

更多相关视频

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas

Published on: January 17, 2018

Establishment and Characterization of Small Bowel Neuroendocrine Tumor Spheroids

Establishment and Characterization of Small Bowel Neuroendocrine Tumor Spheroids

Published on: October 14, 2019

相关概念视频

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: 5-HT₃ Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...